New drug combo aims to keep advanced breast cancer at bay

This study is testing whether adding a drug called pyrotinib to two standard medications (trastuzumab and pertuzumab) can better control advanced HER2-positive breast cancer after initial chemotherapy. It will follow 42 patients in a real-world setting to see if this combination helps delay cancer progression and is safe for long-term use. The goal is to improve the current standard maintenance therapy for patients who have completed their first round of treatment.